Regulatory support for FDA pre-IND meeting: qgrft for the prevention of sars-COV-2 infection
Ended Purchase Order Awarded Last action
- Contract number
- 75N95020P00271
- Awardee
-
Novotech Drug Development Consulting LLC UEI NL1CNS4ZP7X4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $78,956
Award facts
- Opportunity
-
- Regulatory Support for FDA Pre-IND Meeting: QGRFT for the Prevention of SARS-CoV-2 Infection Solicitation · 75N95020Q00145 · Posted Jun 9, 2020
- Contract value 100% obligated
- $78,955.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- Total Small Business
- Competition
- Competed under SAP · 5 offers Simplified Acquisition
- Pricing
- Labor Hours
- Place of performance
- Boulder, CO 80301, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$12,045 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $91,000 |
About this award
The National Institute on Drug Abuse awarded a $78,955.50 purchase order to Novotech Drug Development Consulting LLC (doing business as CBR International, LLC) for regulatory support services related to an FDA pre-Investigational New Drug (IND) meeting for a quinone-generating flavonoid (QGRFT) candidate to prevent SARS-CoV-2 infection. The contract, which was performed in Boulder, Colorado, carried a Total Small Business set-aside designation and utilized a labor hours pricing model. The award was made on June 25, 2020, with an ultimate completion date of June 24, 2021, following a rapid solicitation process that posted on June 9, 2020, and closed on June 17, 2020.
A modification to this contract de-obligated $12,044.50 in expiring fiscal year funding, reducing the total ceiling value from $91,000.00 to $78,955.50. Novotech is a contract research organization specializing in clinical development services and regulatory submissions for FDA applications across therapeutic areas, with prior experience supporting COVID-19 vaccine and treatment development initiatives through federal agencies. This award reflects the government's rapid mobilization of regulatory expertise during the pandemic response period.
Quick answers
Who was awarded contract 75N95020P00271?
75N95020P00271 was awarded to Novotech Drug Development Consulting LLC by National Institute on Drug Abuse (National Institutes of Health) on June 25, 2020.
How much is contract 75N95020P00271 worth?
The government has obligated $78,956 on 75N95020P00271.
Was contract 75N95020P00271 competed?
The extent of competition for 75N95020P00271 was competed under sap. The government received 5 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award